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Diagnosing metastatic renal cell carcinoma (RCC) by fine-nee-
dle aspiration (FNA) can be challenging. Existing antibodies
supporting a diagnosis of RCC, including CD10 and RCC-Ma,
have problems with specificity and interpretation. In this report,
we evaluate the use of two newer immunostains, PAX-2 and g-
H2AX, which to our knowledge have not been studied in FNA
material, in the diagnosis of metastatic RCC and in comparison
with RCC-Ma. 29 cases of metastatic RCC were identified as
well as a TMA of an additional 30 RCC cases. In the case
cohort, RCC-Ma in a membranous pattern of staining identified
15/27 (56%) metastatic RCC, although interpretation was made
difficult in many cases due to focality of staining and non-spe-
cific cytoplasmic staining. PAX-2 stained 23/29 (79%) of tumors
in a nuclear stain, most strongly. Gamma-H2AX stained 19/26
(73%) of metastatic RCC strongly in a nuclear stain. In the
TMA, strong, diffuse nuclear staining with g-H2AX was present
in 22/30 RCC (73%). If weak staining was also included as pos-
itive, 26/30 (87%) were positive. PAX-2 stained RCC TMA with
a lower percentage at 56%, including weaker staining intensity.
Both PAX-2 and g-H2AX demonstrated patchy staining of nor-
mal renal tubules, PAX-2 to a greater extent. Both PAX-2 and
g-H2AX are sensitive markers for the diagnosis of metastatic
RCC, with improved ease of interpretation when compared with
RCC-Ma. A combination of all 3 markers identified 87% of
cases, and failure to stain for both PAX-2 and g-H2AX suggests
against, but does not disprove, a diagnosis of RCC. Diagn.
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Diagnosing metastatic renal cell carcinoma (RCC) by
fine-needle aspiration (FNA) can be a challenge, as often
very few cells are aspirated and morphologic overlap with
other neoplasms and normal tissues exists, depending on
the site. Although there are many features which can sug-
gest a diagnosis of RCC in the absence of immunohisto-
chemical stains,1 these findings may not be entirely spe-
cific. The diagnosis often depends upon immunostains on
the cell block, which is made difficult by the similar lack
of specificity of some commonly used immunostains,
including CD10.2,3 The diagnosis, particularly FNA, can
also be made more difficult by the small size of the sam-
ple and resultant difficulty in evaluating pathologic fea-
tures as well as immunostains.4
The antibody known as renal cell carcinoma marker
(RCC-Ma) was developed as a monoclonal antibody to
normal human kidney proximal tubule,5 and found to be
specific for RCC, both primary and metastatic, in many
studies.4,6 Its use in many institutions, including our own,
has been limited as the stain is often difficult to interpret
and has a low sensitivity, particularly in small biopsies.7–9
In particular, the staining pattern is frequently focal and
difficult to distinguish from the frequent background,
nonspecific staining which is seen in many tissues.10
Staining by RCC-Ma is most clearly demonstrated in clas-
sic cases when immunohistochemical adjuncts to diagno-
sis may not even be necessary.
PAX-2 is another marker which is increasingly being
studied for utility in metastatic RCC, but to our knowl-
edge has not been studied in FNA. PAX-2 is a transcrip-
The University of Michigan Medical School, Department of Pathol-
ogy, Ann Arbor, Michigan
*Correspondence to: Matthew J. Wasco, M.D., The University of
Michigan Medical School, Department of Pathology, 1301 Catherine,
M4211 MSI Ann Arbor, MI 48109-0602.
E-mail: mwasco@med.umich.edu
Received 19 January 2008; Accepted 29 March 2008
DOI 10.1002/dc.20839
Published online in Wiley InterScience (www.interscience.wiley.com).
568 Diagnostic Cytopathology, Vol 36, No 8 ' 2008 WILEY-LISS, INC.
tion factor expressed in epithelial cells of fetal kidneys
and enhanced in certain pathologic conditions. It is being
studied as an emerging marker for diagnosing renal
tumors as well as nephrogenic adenomas.11–13 The advan-
tages of PAX-2 over other currently used antibodies
include ease of interpretation, as PAX-2 stains nuclei of
cells and is less prone to false-positive interpretation than
markers such as RCC-Ma and CD10, which predomi-
nantly stain cell membranes.
Gamma-H2AX is an antibody which specifically reacts
with phosphorylated histone H2AX (at position Ser-139)
and has been shown to be a marker of activated DNA
damage response in tumor cells.14,15 We have previously
shown that g-H2AX is also a potentially useful adjunct to
the diagnosis of metastatic RCC when the differential di-
agnosis includes hepatocellular carcinoma and adrenocor-
tical carcinoma, other clear cell tumors which are often in
the differential diagnosis.9 Our study aims were to see if
g-H2AX was equally sensitive, particularly in FNA, in
diagnosing metastatic RCC, and in addition to compare it
with PAX-2 and RCC-Ma.
Methods
Through a search of the University of Michigan pathology
database, cases of metastatic RCC with cell block mate-
rial available were identified. Standard cytology smears,
cell blocks, and available immunostains were reviewed to
confirm the diagnosis in each case. Cell block preparation
included initial fixation in CytoLyt (Cytyc Corporation,
Boxborough, MA), which is a methanol-based fixative.
They were then processed by routine cell block process-
ing. Paraffin embedded cell block sections were then
stained for g-H2AX (Cell Signaling Technologies, Dan-
vers, MA), PAX-2 (Zymed laboratories), and RCC-Ma
(Novocastra Laboratories Ltd, Newcastle upon Tyne, UK)
according to the manufacturer’s recommended protocols
with some modifications for optimal conditions (described
in our previous paper9). Gamma-H2AX was used at a
dilution of 1:50, RCC-Ma at a dilution of 1:100, and
PAX-2 at 1:100. In addition, a tissue microarray (TMA)
of primary RCC was stained for PAX-2 and g-H2AX.
Stains were reviewed by both pathologists (MJW and
RTP) and the patterns (membranous, cytoplasmic, etc) of
staining as well as the amount (in percentage) of tumor
cells staining were recorded for each tumor. These char-
acteristics were identified by visual estimation. Any back-
ground staining was also recorded. A case was considered
positive when more than 25% of tumor cells stained and
the tumor could easily be distinguished from the back-
ground. Staining was considered negative or equivocal if
background staining and tumor were difficult to distin-
guish, or if fewer than 25% of tumor cells stained. Data
were analyzed using simple statistics to determine the
sensitivity of each marker.
Results
A total of 29 cases of metastatic RCC were identified.
Cases from a wide spectrum of site were available, with
the most common site being lung (Table I). Seventeen of
the cases were clear cell RCC, 3 were papillary, and 8
were of unknown or unclassified subtype. For two of the
cases, lesional tissue was no longer present on the slide
stained for RCC-Ma. This was also true for three of the
29 cases for the g-H2AX-stained slide. Most cases had
more than 100 cells available for immunostaining on the
cell block, the minimum was 25 cells.
Case Cohort Results
A summary of staining of the metastatic RCC cohort with
all three markers is as follows. RCC-Ma in a membranous
pattern of staining identified 15/27 (56%) cases, although
interpretation was made difficult in many cases due to
focality of staining and some non-specific cytoplasmic
staining (Fig. C-1). PAX-2 stained 23/29 (79%) of tumors
in a nuclear stain. The majority were strong staining.
Gamma-H2AX stained 19/26 (73%) of metastatic RCC
strongly in a nuclear stain (Figs. C-1–C-3). For all anti-
bodies, the average percent of cells staining in positive
cases was over 50% (range 30–90%). Both g-H2AX and
PAX-2 stained some background lymphocytes and macro-
phages in a minority of cases. There were no significant
differences in staining patterns or intensity among the dif-
ferent subtypes of RCC, although all three examples of
papillary RCC were positive for all three antibodies. Both
PAX-2 and g-H2AX were easy to interpret when positive,
as positive cases generally displayed a strong nuclear
stain in the majority of tumor cells, with minimal back-
ground staining.
For PAX-2 positive cases, the average percentage of
cells staining positive was 68%. For g-H2AX, the average
was 56% of cells. Of metastatic RCC that were negative
for RCC marker, 4/12 were positive for g-H2AX (in two
Table I. Distribution of Cases in the Cohort
Site Number of cases
Adrenal 1
Femoral head 2




Neck lymph node 3
Pancreas 1
Parotid gland 1
Retroperitoneal lymph node 4
Supraclavicular lymph node 1
Thyroid 1
Vertebral bone 1
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of the 12 cases, tumor was no longer present on the g-
H2AX stained slide) and 6/12 were positive for PAX-2.
Two of the RCC-Ma negative tumors were positive for
PAX-2 but negative for g-H2AX. Four cases were nega-
tive for all three antibodies. There were no cases that
were positive for RCC-Ma but negative for the other two
markers.
Tissue Microarray
For the tissue microarray, strong, diffuse nuclear staining
with g-H2AX was present in 22/30 RCC (73%). If weak
staining was also included as positive, 26/30 (87%) were
positive. PAX-2 stained RCC TMA with a lower percentage
at 56%, including weaker staining intensity (Fig. C-4). Both
PAX-2 and g-H2AX demonstrated patchy staining of nor-
mal renal tubules, PAX-2 to a greater extent.
Discussion
Diagnosing metastatic renal cell carcinoma can be diffi-
cult, in part due to the propensity of the tumor to spread
to a wide variety of sites and tendency to mimic other
types of neoplasm.16 Current strategies include appraisal
Figs. C-1–C-3. Fig. C-1. A case of metastatic RCC to the neck with weak, non-specific or equivocal staining for RCC-Ma (A), positive for PAX-2
(B), and weakly positive for g-H2AX (C). Fig. C-2. A case of metastatic RCC to the neck negative for RCC-Ma (A), and positive for both PAX-2 (B)
and g-H2AX (C). Fig. C-3. A case of metastatic RCC to the parotid positive for RCC-Ma (A), strongly positive for PAX-2 (B) and focally positive for
g-H2AX (C).
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of various morphologic features as well as immuno-
stains such as RCC-Ma,8,16 CD10,3 and increasingly,
PAX-2.11
In this article, we report the comparison of RCC-Ma,
PAX-2, and a new antibody, g-H2AX, in the diagnosis of
metastatic RCC in fine-needle aspiration material. Previ-
ously, we have reported the utility of g-H2AX, primarily
in the differentiation of metastatic RCC from two of its
common mimickers, adrenocortical carcinoma and hepato-
cellular carcinoma.9 Gamma-H2AX, similarly to PAX-2,
has a nuclear pattern of staining (generally strongly) and
has less of the background staining which makes RCC-
Ma a problematic marker for usage in routine clinical
practice in many laboratories.10 These difficulties with
RCC-Ma interpretation often come into play in FNA ma-
terial, when only limited amounts of tumor tissue are
available for study.8
Thus far, there have been limited reports of PAX-2
expression in non-renal tumors,18 and it is to date consid-
ered to be a fairly specific antibody for tumors of renal
origin. But use of this antibody has not yet been widely
accepted, and clinical utility needs to be confirmed by
additional studies. An interesting finding in early studies
is that PAX-2, in some reports, may be less useful in
higher grade renal tumors than in conventional, more
clearly differentiated RCC.19 In our previous study, one
Fig. C-4. A TMA was stained with g-H2AX and PAX-2. Patchy staining of normal renal tubules was seen with both PAX-2 (A) and g-H2AX (B).
Pictured is a case of RCC that was negative for PAX-2 (C) and positive for g-H2AX (D), and also, a case which was positive for both PAX-2 (E) and
g-H2AX (F).
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of the useful features of g-H2AX was that it stained a
high percentage of high-grade (equivalent of Fuhrman nu-
clear grades 3–4) tumors when compared with RCC-Ma.9
As these are the tumors that often defy diagnosis, it may
have clinical relevance particularly in these cases. Tumors
from some other sites have been reported to be positive
for g-H2AX, including breast, melanoma, prostate, and
urinary bladder,14,15 although these studies are limited
and preliminary and have not been supported by addi-
tional studies of clinical relevance.
The results of our study show that all three antibodies
are relatively sensitive for metastatic renal cell carci-
noma, in particular clear cell and papillary subtypes. Our
study did not include any cases of chromophobe RCC,
although several cases were of indeterminate subtype.
RCC-Ma (in a membranous pattern) identified 56% of
metastatic RCC, with several cases equivocal due to dif-
ficulty of interpreting the stain. PAX-2 and g-H2AX (nu-
clear stain) each were more sensitive markers, identify-
ing 79% and 73%, respectively, of metastatic RCC in
our cohort. Both were similarly easy to interpret, staining
approximately half of tumor cells and occasionally stain-
ing background lymphocytes and histiocytes in a minor-
ity of cases. Both g-H2AX and PAX-2 were helpful in
over 50% of the cases in which RCC-Ma was negative
or equivocal, suggesting the utility of these stains. Addi-
tionally, RCC-Ma was never the sole positive antibody.
In total, 87% of cases were positive for at least one of
the markers.
Of note, the data from the TMA of renal cell carcino-
mas cases provided only a 56% sensitivity for PAX-2
(including weak staining cases), compared with 87% for
g-H2AX. This may suggest that the sensitivity of PAX-2
is lower than that reported previously, although in the
actual case cohort the sensitivity was higher.
Although the relationship of the PAX-2 antibody as a
relatively specific marker for renal epithelium has been
studied,12,13 the reasons for relative specificity of g-
H2AX for renal tumors are less clear. Gamma-H2AX is
involved in the cellular repair process, particularly in
regards to double stranded DNA breaks. The exact role of
g-H2AX in the repair process is unknown, but it is known
that foci of H2AX phosphorylation are created within the
damaged DNA areas as part of the multifactorial repair
process.20 H2AX and other linker histones have been
shown to be crucial for nucleosome formation and conse-
quently gene expression controls.14,15 We have shown
previously that most RCC mark with g-H2AX while
another type of tumor often in the differential, hepatocel-
lular carcinoma, does not. The different staining pattern
by g-H2AX suggests that the double-stranded DNA dam-
age control pathway might be involved differently during
the tumorigenesis of these two tumors. Similarly, epige-
netic change such as DNA methylation also involves
different tumor suppressor genes in RCC and HCC.21,22
In conclusion, g-H2AX and PAX-2 are antibodies with
fairly high sensitivity for metastatic RCC. They both have
improved sensitivity and ease of interpretation on FNA
material when compared with RCC-Ma. The combination
of all three markers identifies 87% of metastatic RCC.
Failure to stain for all three markers suggests against a di-
agnosis of RCC, although occasional cases can be nega-
tive for all three. PAX-2 may be less sensitive than previ-
ously reported, although still clinically useful, for the di-
agnosis of metastatic RCC. More clinical studies may be
warranted to fully clarify the utility of both PAX-2 and
g-H2AX in the spectrum of diseases and differential
diagnosis.
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